Neuraminidase inhibitors in patients with underlying airways disease (Q35627874)

9 August 2017

1 reference

title

Neuraminidase inhibitors in patients with underlying airways disease (English)

1 reference

9 August 2017

John C Williamson

1 reference

9 August 2017

P Samuel Pegram

series ordinal

1 reference

9 August 2017

publication date

1 January 2002

1 reference

Treatments in Respiratory Medicine

9 August 2017

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

85-90

1 reference

Influenza-associated morbidity and mortality in young and middle-aged women

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Influenza and the rates of hospitalization for respiratory disease among infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Influenza mortality among the elderly in France, 1980-90: how many deaths may have been avoided through vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Influenza A virus potentiates basophil histamine release caused by endotoxin-induced complement activation. Examination of normal individuals and patients with intrinsic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

The effects of influenza virus infection on FEV1 in asthmatic children. The time-course study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Influenza virus neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

The low potential for drug interactions with zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256597

21 January 2018

Identifiers

DOI

10.1007/BF03256597

1 reference

release_ej5ii3i52rgvxm2clquwdubjke

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ej5ii3i52rgvxm2clquwdubjke

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference